Table 1 Patient characteristics
Group | Level 1 | Level 2 | Level 3 | ||||||
|---|---|---|---|---|---|---|---|---|---|
CDDP (mg/m2) | 35 | 50 | 65 | ||||||
Case number | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 |
Age (years) | 80 | 62 | 80 | 78 | 61 | 80 | 63 | 79 | 80 |
Gender (M, Male/F, Female) | M | M | M | M | M | M | M | F | F |
Performance status | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
HBV infection | - | - | - | - | - | - | + | - | - |
HCV infection | + | + | - | - | - | + | - | + | - |
Alcohol | - | - | + | + | + | - | - | - | - |
Autoimmune hepatitis | - | - | - | - | - | - | - | - | + |
Child-Pugh Score | 6 | 6 | 5 | 6 | 6 | 7 | 5 | 6 | 6 |
Recurrence (Y, Yes/N, No) | Y | Y | Y | Y | Y | Y | Y | Y | Y |
Interval to previous therapy (M) | 6 | 8 | 6 | 23 | 10 | 21 | 13 | 19 | 3 |
Previous therapy | TACE | TAC | TACE | TACE | TAC | TACE | TAC | TACE | TACE |
History of CDDP Administration | Y | Y | N | Y | Y | Y | Y | Y | Y |
Number of tumors | 3 | 2 | 1 | >5 | >5 | 4 | 4 | >5 | >5 |
Maximum tumor size (mm) | 15 | 15 | 14 | 20 | 10 | 34 | 24 | 10 | 30 |
Vascular invasion (Y, Yes/N, No) | N | N | N | N | N | N | N | N | N |
Metastasis (Y, Yes/N, No) | N | N | N | N | N | N | N | N | N |
Stage (UICC) | II | II | I | II | II | II | II | II | II |
Tumor location (PAMLC) | PA | ML | ML | AM | ML | M | P | A | PA |
BSA (m 2 ) | 1.486 | 1.6 | 1.457 | 1.5 | 1.72 | 1.68 | 1.415 | 1.538 | 1.538 |
Ccr (ml/min) | 68 | 118 | 75 | 89 | 121 | 92 | 83 | 95 | 85 |
CDDP (mg/body) | 52 | 56 | 51 | 75 | 86 | 84 | 92 | 100 | 100 |
Miriplatin (mg/body) | 86 | 18 | 80 | 120 | 60 | 60 | 74 | 100 | 120 |